/> The mid-term results showed that 100% of the 9 patients who could be evaluated for efficacy achieved complete remission at the 3-month time point .
100% of patients achieve complete remission of oncolytic virus/PD-1 antibody combination Phase 2 clinical results are positive
Time of Update: 2021-12-02
A few days ago, CG Oncology announced the preliminary results of phase 2 clinical trials of its oncolytic virus therapy CG0070, in combination with the heavy anti-PD-1 antibody Keytruda, in the treatment of non-muscular invasive bladder cancer.
Tianjing Biotech announces that the Phase 2 clinical trial of TJ107 and PD-1 antibody combination drug has been approved by NMPA to start
Time of Update: 2021-11-16
Shanghai, China and Gaithersburg, USA October 18, 2021/PRNewswire/ - Tianjing Bio ("Company") (NASDAQ: IMAB) is a company that is moving from the clinical stage to commercialization
Positive results of Agenus anti-PD-1 monoclonal antibody for treatment of refractory cervical cancer stage 2
Time of Update: 2021-10-11
On August 26, 2021, Agenus announced that its anti-PD-1 monoclonal antibody batilimumab (balstilimab), a single-drug treatment of recurrent/metastatic cervical cancer, was published online in the international peer-reviewed journal.
Gastric Cancer: Pembrolizumab vs. Paclitaxel in the treatment of PD-L1-positive gastric
Time of Update: 2021-09-18
In patients with PD-L1 CPS ≥ 10, the median PFS of the pembrolizumab group and paclitaxel group were 2.
European Union approves Sanofi/Regeneron anti-PD-1 therapy Libtayo: treatment of 2 kinds of advanced cancer
Time of Update: 2021-08-08
Sanofi and its partner Regeneron recently announced that the European Commission (EC) has approved the anti-PD-1 therapy Libtayo (cemiplimab) as a monotherapy for the treatment of two advanced
Hans Biotech initiates Phase 2 clinical trial of CD47/PD-1 bispecific antibody
Time of Update: 2021-06-22
Recently, Hansi Biotechnology announced that it has initiated a phase 2 clinical study of the anti-CD47/PD-1 bispecific antibody HX009 injection, and plans to develop the treatment of advanced solid tumors .
Hans Biotech initiates Phase 2 clinical trial of CD47/PD-1 bispecific antibody
Time of Update: 2021-06-21
com/s/fjv8MhTMzGogWXLKIhQRRg[2] ASCO: Hans Biosciences announced the latest clinical data of anti-CD47/PD-1 bifunctional antibody HX009 injection at the annual meeting of the American Society of Clinical Oncology in 2021.
Fuhong Henlius plans to submit a listing application for phase 2 clinical trial of anti-PD-1 antibody reaching the primary endpoint
Time of Update: 2021-04-19
The primary endpoint reached this time is a single-arm, open, multiple-arm, open-ended, multiple-arm, open-ended, multiple-arm, unresectable or metastatic MSI-H or dMMR solid tumor patient who has failed standard treatments to evaluate the efficacy, safety, and tolerability of HLX10.
Cancer immunotherapy "veteran" IL-2: Can the resurgence of research and development continue to write the PD-1 myth?
Time of Update: 2021-03-24
. For example, the Alkermes Phase II drug candidate nemvaleukin alfa is formed by the fusion of IL-2 variants with the α chain, which blocks the interaction between the candidate drug
Domestic anti-PD-1 therapy! Baiji Shenzhou Baizean ® approved: joint 2 chemotherapy programs first
Time of Update: 2021-01-27
chemotherapy programs for the treatment of first-line advanced squamous non-small cell lung cancer (NSCLC) patients. this is the third ® approved in China by Bai Ze'an and the first lung cancer adaptation. It is worth noting that, more
The PD-1 market "2 plus 4" pattern appears, the competition is becoming more and more intense
Time of Update: 2020-11-18
have also been listed for sale. , eight PD-1/L1-owned enterprises have announced their results for the first half of 2020. first look at how the PD-1 drug, which enters the National Health Insurance Directory, is doing. , according
Lung cancer is overweight! Mercadon Keytruda first-line treatment of PD-L1 high expression lung
Time of Update: 2020-10-06
survival outcomes in these metastasis lung cancer patients. In this study, Keytruda's long-term survival benefits as a single drug are a good example of the significant progress we've made in lung cancer, providing patients with a longer, progress
Anti-Trop-2 ADC drug Trodelvy combined with PD-L1 monoantitic Tecentriq: Treatment of urethral derilopathy and non-small cell lung cancer.
Time of Update: 2020-07-17
second study, Morpheus-Lung, will recruit mNSCLC patients who have received CPI treatment, which is treated only by Tecentriq and Trodelvy, or Dositatha.
BaiOta 2 PD-1 Single Anti-BAT1308 Injection Approved Clinical
Time of Update: 2020-06-15
On May 27, Bai Otay announced that the company's independent research and development of BAT1308 injections by the State Drug Administration approved clinical.
Pfizer and Merck release 2-year update on PD-L1 immunotherapy Bavencio
Time of Update: 2020-06-11
MCC is a rare invasive skin cancer, clinical prognosis is very poor, metastatic MCC mortality rate is higher than melanoma, 1 year survival rate is not more than 50%, 5 yearsurvival rate is not more than 20%. recently, Pfizer
Improving PD-1 Therapeutic EffectS Innovative Combination Therapy Phase 1/2 Clinical Data Positive
Time of Update: 2020-06-01
INO-5401 is a highly optimized synthetic DNA immunotherapy developed by Inovio that encodes a variety of cancer antigens, including hTERT, WT1, and PSMA, designed to activate T cells in a wide range of human cancer patients.
